Pharma BD Deal Intelligence

Mitovera Therapeutics LLC / Foresee Pharmaceuticals Co., Ltd.

2026 · Licensing/Option · $478M · Pending

Foresee Pharmaceuticals' board of directors resolved to license rights to its oral ALDH2 activator program, held through its wholly owned US subsidiary, to Mitovera Therapeutics LLC, a newly formed Delaware entity that is a related party of Foresee. Foresee's US subsidiary is to receive a $5 million upfront payment, milestone payments of up to $473 million, single-digit royalties on sales, and a 19% equity stake in Mitovera. The licensed asset is mirivadelgat (FP-045), a highly selective oral small-molecule allosteric activator of ALDH2, a mitochondrial enzyme. In October 2024 the Taiwan FDA approved a Phase 2 trial of the program in pulmonary hypertension associated with interstitial lung disease, with first patient dosed in May 2025. Foresee framed the transaction as strengthening working capital and shareholder equity while reducing costs and expenses.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →